This effect leads to a synergy with nivolumab treatment, enhancing tumor regression, which was attenuated by CD8+ T cell depletion, highlighting the role of CD8+ T cells in the response to the combination levatinib plus nivolumab [110]. The gene discussed is CD8A; the disease is neoplasm.